Login to Your Account

Flipping the Switch

Buddy, ‘Gilenya’ Spare a Dime? Biogen Tops in Oral MS Space

By Randy Osborne
Staff Writer

Tuesday, October 29, 2013
A surprise delay in the launch of Biogen Idec Inc.’s long-lasting recombinant factor VIII candidate for hemophilia A, Eloctate – partnered with Swedish Orphan Biovitrum (Sobi) – did little to dampen investor joy over third-quarter earnings, thanks to another home run with Tecfidera (dimethyl fumarate).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription